ELI LILLY AND COMPANY Deferred Tax Liabilities, Prepaid Expenses
ELI LILLY AND COMPANY (LLY) had Deferred Tax Liabilities, Prepaid Expenses of $707.00 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesPrepaidExpenses · last filed 2026-02-12
- 2025-12-31: Deferred Tax Liabilities, Prepaid Expenses $707.00M.
- 2024-12-31: Deferred Tax Liabilities, Prepaid Expenses $611.00M.
- 2023-12-31: Deferred Tax Liabilities, Prepaid Expenses $460.60M.
- 2022-12-31: Deferred Tax Liabilities, Prepaid Expenses $546.50M.
| Period end | Deferred Tax Liabilities, Prepaid Expenses |
|---|---|
| 2025-12-31 | $707.00M 10-K · filed 2026-02-12 |
| 2024-12-31 | $611.00M 10-K · filed 2026-02-12 |
| 2023-12-31 | $460.60M 10-K · filed 2025-02-19 |
| 2022-12-31 | $546.50M 10-K · filed 2024-02-21 |
| 2021-12-31 | $560.60M 10-K · filed 2023-02-22 |
| 2020-12-31 | $410.10M 10-K · filed 2022-02-23 |
| 2019-12-31 | $305.90M 10-K · filed 2021-02-17 |
| 2018-12-31 | $240.10M 10-K · filed 2020-02-19 |
| 2017-12-31 | $231.50M 8-K · filed 2019-10-24 |
| 2016-12-31 | $265.30M 10-K · filed 2018-02-20 |
| 2015-12-31 | $317.80M 10-K · filed 2017-02-21 |
| 2014-12-31 | $275.80M 10-K · filed 2016-02-19 |
| 2013-12-31 | $446.20M 10-K · filed 2015-02-19 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |